← All stories
Markets
XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation
LOS ALTOS, California, Aug. 31, 2026 (GLOBE NEWSWIRE) — Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows the treating physician to titrate the dose of budiodarone monthly. First Eu…
Covered by 1 outlet
All coverage · 1 article